B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

TRPC4

MOLECULAR TARGET

transient receptor potential cation channel, subfamily C, member 4

UniProt: AAC05178NCBI Gene: 2206615 compounds

TRPC4 (transient receptor potential cation channel, subfamily C, member 4) is targeted by 15 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting TRPC4

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1m0841.956
2Hexachlorophene1.393
3Methylene Blue1.102
4Amoxapine1.102
5Fluspirilene1.102
6Promethazine1.102
7propionylpromazine hydrochloride1.102
8triflupromazine hydrochloride1.102
92-Chloroadenosine 2-Chloroadenosine.0.691
10Calcimycin0.691
11Carvedilol0.691
12Guanfacine0.691
13Niflumic Acid0.691
14Promazine0.691
15Thioridazine0.691

About TRPC4 as a Drug Target

TRPC4 (transient receptor potential cation channel, subfamily C, member 4) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 15 compounds with documented TRPC4 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

TRPC4 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.